DK2167458T3 - Kirale diacylhydrazin-ligander til modulering af ekspressionen af eksogene gener via et ecdyson-receptor-kompleks - Google Patents

Kirale diacylhydrazin-ligander til modulering af ekspressionen af eksogene gener via et ecdyson-receptor-kompleks Download PDF

Info

Publication number
DK2167458T3
DK2167458T3 DK08754763.4T DK08754763T DK2167458T3 DK 2167458 T3 DK2167458 T3 DK 2167458T3 DK 08754763 T DK08754763 T DK 08754763T DK 2167458 T3 DK2167458 T3 DK 2167458T3
Authority
DK
Denmark
Prior art keywords
butyl
optionally substituted
hydrazide
gene
benzoic acid
Prior art date
Application number
DK08754763.4T
Other languages
English (en)
Inventor
Robert E Hormann
Bing Li
Original Assignee
Intrexon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrexon Corp filed Critical Intrexon Corp
Application granted granted Critical
Publication of DK2167458T3 publication Critical patent/DK2167458T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/18—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
    • A01N43/06—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom five-membered rings
    • A01N43/08—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom five-membered rings with oxygen as the ring hetero atom
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
    • A01N43/06—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom five-membered rings
    • A01N43/10—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom five-membered rings with sulfur as the ring hetero atom
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/24—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with two or more hetero atoms
    • A01N43/26—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with two or more hetero atoms five-membered rings
    • A01N43/28—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with two or more hetero atoms five-membered rings with two hetero atoms in positions 1,3
    • A01N43/30—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with two or more hetero atoms five-membered rings with two hetero atoms in positions 1,3 with two oxygen atoms in positions 1,3, condensed with a carbocyclic ring
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/24—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with two or more hetero atoms
    • A01N43/32—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with two or more hetero atoms six-membered rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C241/00—Preparation of compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C241/04—Preparation of hydrazides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/38—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8217—Gene switch
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8237—Externally regulated expression systems
    • C12N15/8238—Externally regulated expression systems chemically inducible, e.g. tetracycline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Claims (9)

1. Forbindelse valgt fra gruppen bestående af: (R)-3,5-Dim et hyl-benzoesyre N-(1 - ieri- buty I-buty I) -N'-(2-ethyl-3-methoxybenzoyl)-hydrazid; (R)- 3,5-Dim et hyl-benzoesyre N'-benzoyl-N-(1 - ieri- buty I-buty I) - hydrazid; (R)-3,5-Dim et hyl-benzoesyre N-(1 - tert- buty I-bu ty I) -Ν'-(2-met hyl-benzoyl) -hydrazid; (R)-3,5-Dim et hyl-benzoesyre N-(1 - ferf-buty I-bu ty I)-Ν'-(2-fluor-benzoyl)-hydrazid; (R)-3,5-Dim et hyl-benzoesyre Ν'-(2-brom-benzoyl)-N-(1 - ieri-buty l-buty I) -hydrazid; (R)-3,5-Dim et hyl-benzoesyre N-(1 -tert- buty I-bu ty l)-N'-(3-m ethyl-benzoyl) -hydrazid; (R)-3,5-Dim et hyl-benzoesyre N-(1 - tert- buty I-bu ty I) -Ν'-(4-met hyl-benzoyl) -hydrazid; (R)-3,5-Dim et hyl-benzoesyre N-(1 - ieri- buty I-buty I) - Ν'-(2-chlor-py ridin-3-carbonyl)-hydrazid; (R)-3,5-Dim et hyl-benzoesyre N-(1 - ferf- butyl-butyl)-N'-( 6-chlor-pyridin-3-carbonyl)-hydrazid; og (R)-3,5-Dim et hyl-benzoesyre N-(1-ferf-butyl-butyl)-N'-(3-methoxy-2-m et hyl-benzoyl) -hydrazid, eller et farmaceutisk acceptabelt salt deraf. 2. (R)-3,5-dim et hyl-benzoesyre N-(1 - ferf-butyl-butyl)-N'-(2-ethyl-3-methoxy-benzoyl)-hydrazid ifølge krav 1 med et enantiomeroverskud på mindst 95 % fortrinsvis med et enantiomeroverskud på mindst 99 %, eller et farmaceutisk acceptabelt salt deraf. 3. (R)-3,5-dimethyl-benzoesyre N'-benzoyl-N-(1-ferf-butyl-butyO-hydrazid ifølge krav 1 med et enantiomeroverskud på mindst 95 % fortrinsvis med et enantiomeroverskud på mindst 99 %, eller et farmaceutisk acceptabelt salt deraf. 4. (R)-3,5-dim et hyl-benzoesyre N-(1 - tert-buty I-buty I)-Ν'-(2-met hyl-benzoyl)-hydrazid ifølge krav 1 med et enantiomeroverskud på mindst 95 % fortrinsvis med et enantiomeroverskud på mindst 99 %, eller et farmaceutisk acceptabelt salt deraf. 5. (R)-3,5-dim et hyl-benzoesyre N-(1 - tert-buty I-buty I)-Ν'-(2-fluor-benzoyl)-hydrazid ifølge krav 1 med et enantiomeroverskud på mindst 95 % fortrinsvis med et enantiomeroverskud på mindst 99 %, eller et farmaceutisk acceptabelt salt deraf. 6. (R)-3,5-dim et hyl-benzoesyre Ν'-(2-brom -benzoyl) - N-(1 - tert-buty I-bu tyl)-hydrazid ifølge krav 1 med et enantiomeroverskud på mindst 95 % fortrinsvis med et enantiomeroverskud på mindst 99 %, eller et farmaceutisk acceptabelt salt deraf. 7. (R)-3,5-dim et hyl-benzoesyre N-(1 - tert-buty I-buty I)-Ν'-(3-met hyl-benzoyl)-hydrazid ifølge krav 1 med et enantiomeroverskud på mindst 95 % fortrinsvis med et enantiomeroverskud på mindst 99 %, eller et farmaceutisk acceptabelt salt deraf. 8. (R)-3,5-dim et hyl-benzoesyre N-(1 - tert-buty I-buty I)-Ν'-(4-met hyl-benzoyl)-hydrazid ifølge krav 1 med et enantiomeroverskud på mindst 95 % fortrinsvis med et enantiomeroverskud på mindst 99 %, eller et farmaceutisk acceptabelt salt deraf. 9. (R)-3,5-dim et hyl-benzoesyre N-(1 - tert-butyl-butyl)-N'-(2-chlor-py rid in-3-carbonyl)-hydrazid ifølge krav 1 med et enantiomeroverskud på mindst 95 % fortrinsvis med et enantiomeroverskud på mindst 99 %, eller et farmaceutisk acceptabelt salt deraf. 1 0. (R)-3,5-dim et hyl-benzoesyre N-(1 - tert-butyl-butyl)-N'-(6-chlor-py rid in-3-carbonyl)-hydrazid ifølge krav 1 med et enantiomeroverskud på mindst 95 % fortrinsvis med et enantiomeroverskud på mindst 99 %, eller et farmaceutisk acceptabelt salt deraf. 11. (R)-3,5-dimethyl-benzoesyre N-(1 -tert-butyl-butyl)-N'-(3-methoxy-2-methylbenzoyl)-hydrazid ifølge krav 1 med et enantiomeroverskud på mindst 95 % fortrinsvis med et enantiomeroverskud på mindst 99 %, eller et farmaceutisk acceptabelt salt deraf.
12. Farmaceutisk sammensætning omfattende forbindelsen ifølge et hvilket som helst af kravene 1-11 og en farmaceutisk acceptabel bærer.
13. In v/Yro-fremgangsmåde til modulering af ekspressionen af et endogent eller heterologt gen i en værtscelle, hvor værtscellen omfatter en første rekombinant genekspressionskassette omfattende et første polynukleotid der koder for et første polypeptid omfattende: i) et DNA-bindingsdomæne; og ii) et bindingsdomæne for gruppe H nuklearreceptorligand; og en anden rekombinant genekspressionskassette omfattende: i) et responselement i stand til at binde til nævnte DNA-bindingsdomæne; ii) en promoter; og iii) nævnte endogene eller heterologe gen; hvilken fremgangsmåde omfatter at bringe nævnte værtscelle i kontakt med en forbindelse ifølge et hvilket som helst af kravene 1-11; hvor ekspressionen af det endogene eller heterologe gen moduleres.
14. In w'fro-fremgangsmåden ifølge krav 13, hvor værtscellen omfatter: (i) en første rekombinant genekspressionskassette omfattende et polynukleotid, der koder for et første hybridpolypeptid omfattende: (a) et DNA-bindingsdomæne, der genkender et responselement associeret med nævnte gen hvis ekspression skal moduleres; og (b) et ecdyson-receptorligand-bindingsdomæne; (ii) en anden rekombinant genekspressionskassette omfattende et polynukleotid, der koder for et andet hybridpolypeptid omfattende: (a) et transaktiveringsdomæne; og (b) et kimært retinoid-X-receptorligand-bindingsdomæne; og (iii) en tredje rekombinant genekspressionskassette omfattende en polynukleotidsekvens omfattende: (a) et responselement genkendt af DNA-bindingsdomænet af det første hybridpolypeptid; (b) en promoter, der aktiveres af transaktiveringsdomænet af det andet hybridpolypeptid; og (c) nævnte endogene eller heterologe gen.
15. Forbindelse ifølge et hvilket som helst af kravene 1-11 til anvendelse i regulering af endogen eller heterolog genekspression i et transgent individ, hvor nævnte forbindelse bringes i kontakt med et ecdyson-receptor-kompleks i cellerne af nævnte individ, hvor nævnte celler yderligere indeholder en DNA-bindingssekvens for nævnte ecdyson-receptor-kompleks når i kombination med nævnte ligand, og hvor dannelse af et ecdyson-receptor-kompleks-ligand-DNA bindingssekvenskompleks inducerer ekspression af genet, hvor endogen eller heterolog genekspression i et transgent individ reguleres.
16. Forbindelsen ifølge krav 15 til anvendelse i regulering af heterolog genekspression i et transgent individ, hvor nævnte transgene individ omfatter et rekombinant ecdyson-receptor-kompleks i stand til at regulere heterolog genekspression.
17. In vitro-i rem gangsmåde til fremstilling af et polypeptid omfattende trinnene: (a) at vælge en hvirveldyrsværtscelle, som er i alt væsentligt ikke sensitiv i forhold til udsættelse for en forbindelse ifølge et hvilket som helst af kravene 1 til 11; (b) at indføre i værtscellen: (i) et DNA-konstrukt omfattende: (a) et eksogent gen, der koder for polypeptidet; og (b) et responselement; hvor det eksogene gen er under kontrol af responselementet; og (ii) et ecdyson-receptor-kompleks omfattende: a) et DNA-bindingsdomæne, der binder til responselementet; b) et bindingsdomæne for nævnte forbindelse; og c) et transaktiveringsdomæne; og (c) at udsætte cellen for nævnte forbindelse; hvor et polypeptid fremstilles.
18. Forbindelse ifølge et hvilket som helst af kravene 1-11 til anvendelse i modulering af ekspressionen af et eksogent gen hos et individ, hvor cellerne af individet omfatter et genekspression-moduleringssystem.
9. Forbindelsen til anvendelse ifølge krav 18, hvor nævnte eksogene gen koder for human IL-1 2.
DK08754763.4T 2007-05-29 2008-05-29 Kirale diacylhydrazin-ligander til modulering af ekspressionen af eksogene gener via et ecdyson-receptor-kompleks DK2167458T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94052507P 2007-05-29 2007-05-29
PCT/US2008/006757 WO2008153801A1 (en) 2007-05-29 2008-05-29 Chiral diachylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex

Publications (1)

Publication Number Publication Date
DK2167458T3 true DK2167458T3 (da) 2018-06-18

Family

ID=40130032

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08754763.4T DK2167458T3 (da) 2007-05-29 2008-05-29 Kirale diacylhydrazin-ligander til modulering af ekspressionen af eksogene gener via et ecdyson-receptor-kompleks

Country Status (15)

Country Link
US (6) US8076517B2 (da)
EP (2) EP3357904B1 (da)
JP (4) JP5881291B2 (da)
KR (1) KR101528378B1 (da)
CN (2) CN101848887A (da)
BR (1) BRPI0811348B1 (da)
CA (1) CA2689137C (da)
DK (1) DK2167458T3 (da)
ES (1) ES2672513T3 (da)
IL (2) IL202377A (da)
MX (4) MX2009012834A (da)
NZ (1) NZ582013A (da)
RU (2) RU2490253C2 (da)
WO (1) WO2008153801A1 (da)
ZA (1) ZA200909144B (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456315B2 (en) 2003-02-28 2008-11-25 Intrexon Corporation Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
MX2009012834A (es) 2007-05-29 2010-05-17 Intrexon Corp Ligandos quirales de diacilhidrazina para modular la expresion de genes exogenos por medio de un complejo receptor de ecdisona.
EP2205249B1 (en) 2007-09-28 2018-11-07 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
KR101740205B1 (ko) * 2007-10-08 2017-05-25 인트렉손 코포레이션 가공된 수지상 세포 및 암의 치료를 위한 이의 용도
CA2739902A1 (en) 2008-10-08 2010-04-15 Intrexon Corporation Engineered cells expressing multiple immunomodulators and uses thereof
EP2350090B1 (en) 2008-10-17 2015-06-03 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
MY179342A (en) 2009-10-14 2020-11-04 Xenon Pharmaceuticals Inc Synthetic methods for spiro-oxindole compounds
WO2011106729A2 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
JP6189754B2 (ja) 2011-03-04 2017-08-30 イントレキソン コーポレーション タンパク質を条件的に発現するベクター
AU2013202421B2 (en) * 2011-09-08 2015-03-19 Intrexon Corporation Crystalline diacylhydrazine and the use thereof
CA3061802C (en) * 2011-09-08 2022-04-05 Intrexon Corporation Crystalline diacylhydrazine and the use thereof
WO2014144380A1 (en) * 2013-03-15 2014-09-18 Intrexon Corporation Boron-containing diacylhydrazines
US10807944B2 (en) * 2014-04-04 2020-10-20 University Of Florida Research Foundation, Inc. HDAC inhibitor compounds and methods of treatment
SG11201701944WA (en) 2014-09-17 2017-04-27 Intrexon Corp Boron-containing diacylhydrazine compounds
AR103636A1 (es) 2015-02-05 2017-05-24 Teva Pharmaceuticals Int Gmbh Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
JP2018526338A (ja) * 2015-07-17 2018-09-13 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 置換アリールおよびヘテロアリールカルボン酸ヒドラジドまたはその塩ならびに植物のストレス耐性を増強するためのその使用
CA3004742A1 (en) 2015-11-11 2017-05-18 Intrexon Corporation Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies
EP3443001A4 (en) 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
UY37343A (es) 2016-07-25 2018-02-28 Intrexon Corp Control del fenotipo en plantas
EA201990864A1 (ru) 2016-11-09 2019-11-29 Конструкции для экспрессии фратаксина
WO2019173463A1 (en) 2018-03-06 2019-09-12 Intrexon Corporation Hepatitis b vaccines and uses of the same
US20210395773A1 (en) * 2018-06-27 2021-12-23 Precigen, Inc. In vivo controlled combination therapy for treatment of cancer
CN113651729B (zh) * 2021-08-30 2022-10-28 西安交通大学 一种铁催化4-氨基化醇的制备方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US4985461A (en) 1985-10-21 1991-01-15 Rohm And Haas Company Insecticidal N'-substituted-N,N'-diacylhydrazines
US5225443A (en) * 1986-05-01 1993-07-06 Rohm And Haas Company Insecticidal N'-substituted-N'-substituted N,N'-diacylhydrazines
US4981784A (en) 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
AU637573B2 (en) 1988-06-16 1993-06-03 Dow Agrosciences Llc Hydrazine derivatives for pharmaceutical use
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
CA2075192A1 (en) 1990-03-22 1991-09-23 Anthony E. Oro Insect retinoid receptor compositions and methods
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
NZ240155A (en) * 1990-10-29 1992-10-28 Ishihara Sangyo Kaisha Heterocyclyl acyl and (hexahydro) indanyl acyl substituted hydrazine derivatives, preparation thereof and pesticidal compositions
IL100643A (en) 1991-01-25 1996-10-31 Nippon Kayaku Kk History of hydrazine and pesticides containing these histories as an active ingredient
US6013836A (en) * 1992-02-28 2000-01-11 Rohm And Haas Company Insecticidal N'-substituted-N,N'-disubstitutedhydrazines
US5530028A (en) 1992-11-23 1996-06-25 Rohm And Haas Company Insecticidal N'-substituted-N,N'-diacylhydrazines
US5250731A (en) 1992-03-17 1993-10-05 E. I. Du Pont De Nemours And Company Preparation of optically active hydrazines and amines
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
US5482962A (en) 1994-07-22 1996-01-09 Rohm And Haas Company Insecticidal N,N'-disubstituted-N-N'-diacylhydrazines
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
ATE293699T1 (de) 1995-03-03 2005-05-15 Syngenta Participations Ag Kontrolle der pflanzengenexpression durch rezeptor-vermittelte transaktivation in gegenwart von einem chemischen ligand
EP0910652B1 (en) 1996-04-05 2014-10-08 The Salk Institute For Biological Studies Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto
US6723531B2 (en) 1996-04-05 2004-04-20 The Salk Institute For Biological Studies Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
AU738494B2 (en) 1997-07-10 2001-09-20 Salk Institute For Biological Studies, The Modified lepidopteran receptors and hybrid multifunctional proteins for use in regulation of transgene expression
US6333318B1 (en) 1998-05-14 2001-12-25 The Salk Institute For Biological Studies Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
US6258603B1 (en) 1998-06-17 2001-07-10 Rohm And Haas Company Ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
DE19831710A1 (de) * 1998-07-15 2000-01-20 Merck Patent Gmbh Diacylhydrazinderivate
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
DE19932796A1 (de) * 1999-07-14 2001-01-18 Merck Patent Gmbh Diacylhydrazinderivate
AU2420101A (en) * 1999-12-23 2001-07-09 Astrazeneca Ab Method and composition for the treatment of pain
ATE338135T1 (de) 2000-03-22 2006-09-15 Rheogene Holdings Inc Induziertes genexpressionssystem basierend auf ecdysonrezeptoren
US20040033600A1 (en) 2001-03-21 2004-02-19 Palli Subba Reddy Ecdysone receptor-based inducible gene expression system
JP2004509965A (ja) * 2000-09-29 2004-04-02 アストラゼネカ・アクチエボラーグ １，２，５，１０−テトラヒドロピリダジノ［４，５−ｂ］キノリン−１，１０−ジオン及び疼痛治療のためのその使用
DE60121978D1 (de) 2000-09-29 2006-09-14 Astrazeneca Ab 7-CHLOR-4-HYDROXY-2-(2-PYRIDYLETHYL)-1,2,5,10-TETRAHYDROPYRIDAZINOi4,5-BöCHINOLIN-1,10-DIONE UND IHRE VERWENDUNG ZUR BEHANDLUNG VON SCHMERZEN
US8105825B2 (en) 2000-10-03 2012-01-31 Intrexon Corporation Multiple inducible gene regulation system
CA2445796C (en) 2001-02-20 2014-09-16 Rheogene, Inc. Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
JP4955905B2 (ja) 2001-02-20 2012-06-20 イントレキソン コーポレーション キメラレチノイドｘ受容体および新規エクジソン受容体−ベースの誘導性遺伝子発現システムにおけるそれらの使用
WO2002066615A2 (en) 2001-02-20 2002-08-29 Rheogene, Inc. Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
MXPA03007493A (es) 2001-02-20 2004-10-15 Rheogene Holdings Inc Nuevo sistema de expresion genetica inducible a base de receptor de ecdisona/receptor x retinoide de invertebrado.
MXPA04002810A (es) 2001-09-26 2005-06-06 Rheogene Holdings Inc Acidos nucleicos receptores de ecdisona de saltarilla, polipeptidos, y sus usos.
MXPA04002808A (es) 2001-09-26 2005-06-06 Rheogene Holdings Inc Acidos nucleicos receptores de ecdisona de mosca blanca, polipeptidos, y sus usos.
WO2003074534A1 (en) 2002-03-01 2003-09-12 The Trustees Of Columbia University In The City Of New York Reagents for asymmetric allylation, aldol, and tandem aldol and allylation reactions
US20050228016A1 (en) 2002-06-13 2005-10-13 Enrique Michelotti Tetrahydroquinolines for modulating the expression of exogenous genes via an ecdysone receptor complex
US20040049437A1 (en) 2002-09-11 2004-03-11 Govone Solutions, Lp Method, system and computer program product for automating transaction tax calculation
US7304161B2 (en) 2003-02-10 2007-12-04 Intrexon Corporation Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
US7304162B2 (en) 2003-02-21 2007-12-04 Intrexon Corporation Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7456315B2 (en) 2003-02-28 2008-11-25 Intrexon Corporation Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
JP2007515412A (ja) * 2003-12-10 2007-06-14 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング ジアシルヒドラジン誘導体
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
JP2008280336A (ja) * 2007-04-11 2008-11-20 Sumitomo Chemical Co Ltd アミド化合物の製造方法
JP2008280341A (ja) * 2007-04-12 2008-11-20 Sumitomo Chemical Co Ltd ヒドラジド化合物およびその防除用途
MX2009012834A (es) 2007-05-29 2010-05-17 Intrexon Corp Ligandos quirales de diacilhidrazina para modular la expresion de genes exogenos por medio de un complejo receptor de ecdisona.

Also Published As

Publication number Publication date
JP2018080189A (ja) 2018-05-24
KR101528378B1 (ko) 2015-06-11
EP2167458A1 (en) 2010-03-31
US9598355B2 (en) 2017-03-21
RU2013121780A (ru) 2014-11-20
US8884060B2 (en) 2014-11-11
KR20100032393A (ko) 2010-03-25
CA2689137C (en) 2017-05-02
JP5881291B2 (ja) 2016-03-09
CA2689137A1 (en) 2008-12-18
JP2010531297A (ja) 2010-09-24
IL202377A (en) 2016-07-31
CN101848887A (zh) 2010-09-29
MX2009012834A (es) 2010-05-17
US20200270225A1 (en) 2020-08-27
RU2640807C2 (ru) 2018-01-12
IL230641A (en) 2017-11-30
US20150099636A1 (en) 2015-04-09
WO2008153801A8 (en) 2011-05-19
RU2490253C2 (ru) 2013-08-20
US20120316066A1 (en) 2012-12-13
MX365540B (es) 2019-06-06
MX363066B (es) 2019-03-07
US10633361B2 (en) 2020-04-28
JP6270801B2 (ja) 2018-01-31
EP2167458A4 (en) 2013-12-18
US8076517B2 (en) 2011-12-13
JP6516826B2 (ja) 2019-05-22
EP3357904A1 (en) 2018-08-08
CN104761466A (zh) 2015-07-08
EP2167458B1 (en) 2018-03-14
NZ582013A (en) 2012-03-30
US20120116090A1 (en) 2012-05-10
RU2009145642A (ru) 2011-07-10
US20170204079A1 (en) 2017-07-20
BRPI0811348B1 (pt) 2022-02-08
BRPI0811348A2 (pt) 2015-07-28
AU2008263122A1 (en) 2008-12-18
WO2008153801A1 (en) 2008-12-18
IL230641A0 (en) 2014-03-31
IL202377A0 (en) 2010-06-30
EP3357904B1 (en) 2022-07-06
ES2672513T3 (es) 2018-06-14
JP2016065075A (ja) 2016-04-28
US20090163592A1 (en) 2009-06-25
JP2014193875A (ja) 2014-10-09
ZA200909144B (en) 2012-03-28
AU2008263122B2 (en) 2014-04-24
MX339349B (es) 2016-05-20
JP6215767B2 (ja) 2017-10-18

Similar Documents

Publication Publication Date Title
US20200270225A1 (en) Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex
DK2455375T3 (da) Diacylhydrazinligander til modulering af ekspressionen af eksogene gener i pattedyrssystemer via et ecdyson-receptorkompleks
DK1601354T3 (da) Oxadiazolinligander til modulering af ekspressionen af exogene gener via et ecdysonreceptorkompleks
DK2463269T3 (da) Biotilgængelige diacylhydrazinligander til modulering af ekspressionen af exogene gener via et ecdysonreceptorkompleks
CA2489590C (en) Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
AU2008263122C1 (en) Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex
AU2013204101B2 (en) Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex